pentobarbital will minimize the extent or result of elbasvir/grazoprevir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic outcome of elbasvir/grazoprevir could be lowered if coadministered with potent CYP3A inducers and is also hence contraindicated.pentobarbital will reduce the level or influence of abir